GSA Capital Partners LLP Has $78,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

GSA Capital Partners LLP decreased its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 95.5% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 27,350 shares of the company’s stock after selling 578,313 shares during the quarter. GSA Capital Partners LLP’s holdings in Xeris Biopharma were worth $78,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Simplicity Wealth LLC bought a new stake in shares of Xeris Biopharma during the second quarter worth $27,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Xeris Biopharma in the third quarter worth about $35,000. Bayesian Capital Management LP bought a new stake in Xeris Biopharma during the 1st quarter worth about $37,000. Allspring Global Investments Holdings LLC lifted its position in Xeris Biopharma by 4,512.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock valued at $37,000 after purchasing an additional 15,929 shares during the period. Finally, Asset Management Group Inc. lifted its position in Xeris Biopharma by 130.7% during the 2nd quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after purchasing an additional 15,000 shares during the period. 42.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

XERS has been the subject of several analyst reports. Piper Sandler cut shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Monday, November 11th. HC Wainwright raised their price objective on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research note on Monday, November 11th.

Xeris Biopharma Trading Down 0.3 %

Shares of XERS opened at $3.08 on Tuesday. The stock has a market cap of $459.17 million, a P/E ratio of -6.84 and a beta of 2.70. The stock’s 50-day moving average price is $3.04 and its two-hundred day moving average price is $2.60. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.69 and a 1 year high of $3.64.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.